Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Neurodegeneration
Published in: Molecular Neurodegeneration 1/2016

Open Access 01-12-2016 | Review

LRRK2 at the interface of autophagosomes, endosomes and lysosomes

Authors: Dorien A. Roosen, Mark R. Cookson

Published in: Molecular Neurodegeneration | Issue 1/2016

Login to get access

Abstract

Over the past 20 years, substantial progress has been made in identifying the underlying genetics of Parkinson’s disease (PD). Of the known genes, LRRK2 is a major genetic contributor to PD. However, the exact function of LRRK2 remains to be elucidated. In this review, we discuss how familial forms of PD have led us to hypothesize that alterations in endomembrane trafficking play a role in the pathobiology of PD. We will discuss the major observations that have been made to elucidate the role of LRRK2 in particular, including LRRK2 animal models and high-throughput proteomics approaches. Taken together, these studies strongly support a role of LRRK2 in vesicular dynamics. We also propose that targeting these pathways may not only be beneficial for developing therapeutics for LRRK2-driven PD, but also for other familial and sporadic cases.
Literature
1.
Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol. 2002;51:296–301.CrossRefPubMed
2.
Zimprich A, Müller-Myhsok B, Farrer M, Leitner P, Sharma M, Hulihan M, et al. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet. 2004;74:11–9.CrossRefPubMed
3.
Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson’s disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain. 2005;128:2786–96.CrossRefPubMed
4.
Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ, et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology. 2004;62:1619–22.CrossRefPubMed
5.
Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601–7.CrossRefPubMed
6.
Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, et al. Lrrk2 pathogenic substitutions in Parkinson’s disease. Neurogenetics. 2005;6:171–7.CrossRefPubMed
7.
Zabetian CP, Samii A, Mosley AD, Roberts JW, Leis BC, Yearout D, et al. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology. 2005;65:741–4.CrossRefPubMed
8.
Di Fonzo A, Rohe C, Ferreira J, Chien H, Vacca L, Stocchi F, et al. A frequent gene mutation associated with autosomal dominant Parkinson’s disease. Lancet. 2005;365:412–5.CrossRefPubMed
9.
Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, et al. A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet. 2005;365:415–6.PubMed
10.
Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, Kowa H, et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol. 2005;57:918–21.CrossRefPubMed
11.
Paisán-Ruiz C, Lewis PA, Singleton AB. LRRK2: cause, risk, and mechanism. J Park Dis. 2013;3:85–103.
12.
13.
Cookson MR. LRRK2 pathways leading to neurodegeneration. Curr Neurol Neurosci Rep. 2015;15:564.CrossRef
14.
Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet (Nature Publishing Group). 2014;46:989–93.
15.
16.
Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson’s disease and parkinsonism. Ann Neurol. 2006;60:389–98.CrossRefPubMed
17.
Rudenko IN, Cookson MR. Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications. Neurotherapeutics. 2014;11:738–50.CrossRefPubMedPubMedCentral
18.
Lewis PA, Greggio E, Beilina A, Jain S, Baker A, Cookson MR. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun. 2007;357:668–71.CrossRefPubMedPubMedCentral
19.
Daniẽls V, Vancraenenbroeck R, Law BMH, Greggio E, Lobbestael E, Gao F, et al. Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem. 2011;116:304–15.CrossRefPubMedPubMedCentral
20.
Liao J, Wu C-X, Burlak C, Zhang S, Sahm H, Wang M, et al. Parkinson disease-associated mutation R1441H in LRRK2 prolongs the “active state” of its GTPase domain. Proc Natl Acad Sci U S A. 2014;111:4055–60.CrossRefPubMedPubMedCentral
21.
Guo L, Gandhi PN, Wang W, Petersen RB, Wilson-Delfosse AL, Chen SG. The Parkinson’s disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res. 2007;313:3658–70.CrossRefPubMedPubMedCentral
22.
Rosenbusch KE, Kortholt A. Activation mechanism of LRRK2 and its cellular functions in Parkinson’s disease. Park Dis. 2016;2016:7351985.
23.
Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA. LRRK2 in Parkinson’s disease: protein domains and functional insights. Trends Neurosci. 2006;29:286–93.CrossRefPubMed
24.
Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O’Neill E, Meitinger T, et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet. 2006;15:223–32.CrossRefPubMed
25.
Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, Daniels V, et al. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem. 2008;283:16906–14.CrossRefPubMedPubMedCentral
26.
Zdenek B, Smith KA, Lavoie MJ. Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry (Mosc). 2010;49:5511–23.CrossRef
27.
Guaitoli G, Raimondi F, Gilsbach BK, Gómez-Llorente Y, Deyaert E, Renzi F, et al. Structural model of the dimeric Parkinson’s protein LRRK2 reveals a compact architecture involving distant interdomain contacts. Proc Natl Acad Sci (National Academy of Sciences). 2016;113:E4357–66.CrossRef
28.
Beilina A, Cookson MR. Genes associated with Parkinson’s disease: regulation of autophagy and beyond. J. Neurochem. 2015;n/a – n/a.
29.
Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired Degradation of Mutant α -Synuclein by Chaperone-Mediated Autophagy. Science. 2004;305(5688):1292–5.
30.
Cuervo AM, Wong E. Chaperone-mediated autophagy: roles in disease and aging. Cell Res (Nature Publishing Group). 2014;24:92–104.
31.
Li W. Stabilization of -synuclein protein with aging and familial Parkinson’s disease-linked A53T mutation. J Neurosci. 2004;24:7400–9.CrossRefPubMed
32.
Kumaran R, Cookson MR. Pathways to parkinsonism redux: convergent pathobiological mechanisms in genetics of Parkinson’s disease. Hum Mol Genet. 2015;9:1–37.CrossRef
33.
Jovic M, Sharma M, Rahajeng J, Caplan S. The early endosome: a busy sorting station for proteins at the crossroads. Histol Histopathol. 2010;25:99–112.PubMedPubMedCentral
34.
35.
Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol. 2009;10:513–25.CrossRefPubMed
36.
Marat AL, Haucke V. Phosphatidylinositol 3 -phosphates — at the interface between cell signalling and membrane traffic. EMBO J. 2016;35:561–79.
37.
Vanlandingham PA, Ceresa BP. Rab7 Regulates Late Endocytic Trafficking Downstream of Multivesicular Body Biogenesis and Cargo Sequestration *. J Biol Chem. 2009;284:12110–24.
38.
Huotari J, Helenius A. Endosome maturation. EMBO J (Nature Publishing Group). 2011;30:3481–500.
39.
40.
Wen-wen L, Jian L, Jin-ku B. Microautophagy: lesser-known self-eating. J Cell Mol Life Sci. 2012;69:1125–36.CrossRef
41.
42.
Behrends C, Sowa ME, Gygi SP, Harper JW. Network organization of the human autophagy system. Nature (Nature Publishing Group). 2010;466:68–76.
43.
Vicinanza M, Korolchuk V, Ashkenzai A, Puri C, Menzies F, Clarke J, et al. PI(5)P regulates autophagosome biogenesis. Mol Cell Biol. 2015;57.
44.
45.
46.
Xu Z, Yang L, Xu S, Zhang Z, Cao Y. The receptor proteins: pivotal roles in selective autophagy. Acta Biochim Biophys Sin. 2015;47:571–80.CrossRefPubMed
47.
Bitto A, Lerner CA, Nacarelli T, Crowe E, Torres C, Sell C. P62/SQSTM1 at the interface of aging, autophagy, and disease. Age Dordr Neth. 2014;36:9626.CrossRef
48.
49.
Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol. 2006;60:557–69.CrossRefPubMed
50.
Higashi S, Biskup S, West AB, Trinkaus D, Dawson VL, Faull RLM, et al. Localization of Parkinson’s disease-associated LRRK2 in normal and pathological human brain. Brain Res. 2007;1155:208–19.CrossRefPubMed
51.
Alegre-Abarrategui J, Christian H, Lufino MMP, Mutihac R, Venda LL, Ansorge O, et al. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet. 2009;18:4022–34.CrossRefPubMedPubMedCentral
52.
Tong Y, Yamaguchi H, Giaime E, Boyle S, Kopan R, Kelleher RJ, et al. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A. 2010;107:9879–84.CrossRefPubMedPubMedCentral
53.
Herzig MC, Kolly C, Persohn E, Theil D, Schweizer T, Hafner T, et al. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet. 2011;20:4209–23.CrossRefPubMedPubMedCentral
54.
Tong Y, Giaime E, Yamaguchi H, Ichimura T, Liu Y, Si H, et al. Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener. 2012;7:2.CrossRefPubMedPubMedCentral
55.
Dodson MW, Zhang T, Jiang C, Chen S, Guo M. Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum Mol Genet. 2012;21:1350–63.CrossRefPubMed
56.
Sakaguchi-Nakashima A, Meir JY, Jin Y, Matsumoto K, Hisamoto N. LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr Biol. 2007;17:592–8.CrossRefPubMed
57.
Schapansky J, Nardozzi JD, Felizia F, LaVoie MJ. Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy. Hum Mol Genet. 2014;23:4201–14.CrossRefPubMedPubMedCentral
58.
Manzoni C, Mamais A, Dihanich S, Abeti R, Soutar MPM, Plun-Favreau H, et al. Inhibition of LRRK2 kinase activity stimulates macroautophagy. Biochim Biophys Acta (The Authors). 1833;2013:2900–10.
59.
Saez-Atienzar S, Bonet-Ponce L, Blesa JR, Romero FJ, Murphy MP, Jordan J, et al. The LRRK2 inhibitor GSK2578215A induces protective autophagy in SH-SY5Y cells: involvement of Drp-1-mediated mitochondrial fission and mitochondrial-derived ROS signaling. Cell Death Dis. 2014;5:e1368.CrossRefPubMedPubMedCentral
60.
Manzoni C, Mamais A, Roosen DA, Dihanich S, Soutar MPM, Plun-Favreau H, et al. mTOR independent regulation of macroautophagy by Leucine Rich Repeat Kinase 2 via Beclin-1. Sci Rep. 2016;6:35106.CrossRefPubMedPubMedCentral
61.
Baptista MAS, Dave KD, Frasier MA, Sherer TB, Greeley M, Beck MJ, et al. Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. PLoS One. 2013;8:e80705.CrossRefPubMedPubMedCentral
62.
Ness D, Ren Z, Gardai S, Sharpnack D, Johnson VJ, Brennan RJ, et al. Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis. PLoS One. 2013;8:e66164.CrossRefPubMedPubMedCentral
63.
Manzoni C, Mamais A, Dihanich S, McGoldrick P, Devine MJ, Zerle J, et al. Pathogenic Parkinson’s disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation. Biochem Biophys Res Commun (Elsevier Inc). 2013;441:862–6.CrossRef
64.
Plowey ED, Cherra SJ, Liu YJ, Chu CT. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem. 2008;105:1048–56.CrossRefPubMedPubMedCentral
65.
Gómez-Suaga P, Luzón-Toro B, Churamani D, Zhang L, Bloor-Young D, Patel S, et al. Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum Mol Genet. 2012;21:511–25.CrossRefPubMed
66.
Sánchez-Danés A, Richaud-Patin Y, Carballo-Carbajal I, Jiménez-Delgado S, Caig C, Mora S, et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson’s disease. EMBO Mol Med. 2012;4:380–95.CrossRefPubMedPubMedCentral
67.
Reinhardt P, Schmid B, Burbulla LF, Schöndorf DC, Wagner L, Glatza M, et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell. 2013;12:354–67.CrossRefPubMed
68.
Bravo-San Pedro JM, Niso-Santano M, Gómez-Sánchez R, Pizarro-Estrella E, Aiastui-Pujana A, Gorostidi A, et al. The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway. Cell Mol Life Sci. 2013;70:121–36.CrossRefPubMed
69.
Ramonet D, Daher JPL, Lin BM, Stafa K, Kim J, Banerjee R, et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One. 2011;6:e18568.CrossRefPubMedPubMedCentral
70.
Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, Rueter SM, et al. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci Off J Soc Neurosci. 2001;21:8053–61.
71.
72.
Waschbüsch D, Michels H, Strassheim S, Ossendorf E, Kessler D, Gloeckner CJ, et al. LRRK2 transport is regulated by its novel interacting partner Rab32. PLoS One. 2014;9:e111632.CrossRefPubMedPubMedCentral
73.
Beilina A, Rudenko IN, Kaganovich A, Civiero L, Chau H, Kalia SK, et al. Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A. 2014;111:2626–31.CrossRefPubMedPubMedCentral
74.
Fukuzono T, Pastuhov SI, Fukushima O, Li C, Hattori A, Iemura S-I, et al. Chaperone complex BAG2-HSC70 regulates localization of Caenorhabditis elegans leucine-rich repeat kinase LRK-1 to the Golgi. Genes Cells Devoted Mol Cell Mech. 2016;21:311–24.CrossRef
75.
Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M, et al. Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab GTPases. eLife. eLife Sciences Publications, Ltd; 2016;5. doi:10.​7554/​eLife.​12813.
76.
77.
Shin N, Jeong H, Kwon J, Heo HY, Kwon JJ, Yun HJ, et al. LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res. 2008;314:2055–65.CrossRefPubMed
78.
Kuwahara T, Inoue K, D’Agati VD, Fujimoto T, Eguchi T, Saha S, et al. LRRK2 and RAB7L1 coordinately regulate axonal morphology and lysosome integrity in diverse cellular contexts. Sci Rep (Nature Publishing Group). 2016;6:29945.
79.
Dodson MW, Leung LK, Lone M, Lizzio MA, Guo M. Novel ethyl methanesulfonate (EMS)-induced null alleles of the Drosophila homolog of LRRK2 reveal a crucial role in endolysosomal functions and autophagy in vivo. Dis Model Mech. 2014;7:1351–63.CrossRefPubMedPubMedCentral
80.
81.
Gómez-Suaga P, Rivero-Ríos P, Fdez E, Blanca Ramírez M, Ferrer I, Aiastui A, et al. LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity. Hum Mol Genet. 2014;23:6779–96.CrossRefPubMed
82.
Cho HJ, Yu J, Xie C, Rudrabhatla P, Chen X, Wu J, et al. Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export. EMBO J. 2014;33:2314–31.CrossRefPubMedPubMedCentral
83.
Matta S, Van Kolen K, da Cunha R, van den Bogaart G, Mandemakers W, Miskiewicz K, et al. LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron. 2012;75:1008–21.CrossRefPubMed
84.
Arranz AM, Delbroek L, Van Kolen K, Guimarães MR, Mandemakers W, Daneels G, et al. LRRK2 functions in synaptic vesicle endocytosis through a kinase-dependent mechanism. J. Cell Sci. 2014;128:541–52.
85.
Soukup S-F, Kuenen S, Vanhauwaert R, Manetsberger J, Hernández-Díaz S, Swerts J, et al. A LRRK2-Dependent EndophilinA Phosphoswitch Is Critical for Macroautophagy at Presynaptic Terminals. Neuron. 2016;92:6982–7.
86.
Okatsu K, Koyano F, Kimura M, Kosako H, Saeki Y, Tanaka K, et al. Phosphorylated ubiquitin chain is the genuine Parkin receptor. J Cell Biol. 2015;209:111–28.CrossRefPubMedPubMedCentral
87.
Cookson MR. Parkinsonism Due to Mutations in PINK1, Parkin, and DJ-1 and Oxidative Stress and Mitochondrial Pathways. Cold Spring Harb. Perspect. Med. 2012;2:1–11.
88.
Kane LA, Lazarou M, Fogel AI, Li Y, Yamano K, Sarraf SA, et al. PINK1 phosphorylates ubiquitin to activate parkin E3 ubiquitin ligase activity. J Cell Biol. 2014;205:143–53.CrossRefPubMedPubMedCentral
89.
Koyano F, Okatsu K, Kosako H, Tamura Y, Go E, Kimura M, et al. Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature (Nature Publishing Group). 2014;510:162–6.
90.
Thomas KJ, McCoy MK, Blackinton J, Beilina A, van der Brug M, Sandebring A, et al. DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet. 2011;20:40–50.CrossRefPubMed
91.
Wang X, Petrie TG, Liu Y, Liu J, Fujioka H, Zhu X. Parkinson’s disease-associated DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction. J Neurochem. 2012;121:830–9.CrossRefPubMedPubMedCentral
92.
Burchell VS, Nelson DE, Sanchez-Martinez A, Delgado-Camprubi M, Ivatt RM, Pogson JH, et al. The Parkinson’s disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy. Nat Neurosci. 2013;16:1257–65.CrossRefPubMed
93.
Xilouri M, Vogiatzi T, Vekrellis K, Park D, Stefanis L. Abberant α-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS One. 2009;4:16–20.CrossRef
94.
Zimprich A, Benet-Pagès A, Struhal W, Graf E, Eck SH, Offman MN, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset parkinson disease. Am J Hum Genet. 2011;89:168–75.CrossRefPubMedPubMedCentral
95.
Vilariño-Güell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, et al. VPS35 mutations in parkinson disease. Am J Hum Genet. 2011;89:162–7.CrossRefPubMedPubMedCentral
96.
Ramirez A, Heimbach A, Gründemann J, Stiller B, Hampshire D, Cid LP, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Genetics. 2006;38:1184–91.PubMed
97.
Elsayed LEO, Drouet V, Usenko T, Mohammed IN, Hamed AAA, Elseed MA, et al. A novel nonsense mutation in DNAJC 6 expands the phenotype of autosomal-recessive juvenile-onset Parkinson’s disease. Ann Neurol. 2016;79:335–7.CrossRefPubMed
98.
Olgiati S, Quadri M, Fang M, Rood JPMA, Saute JA, Chien HF, et al. DNAJC6 mutations associated with early-onset Parkinson’s disease. Ann Neurol. 2016;79:244–56.CrossRefPubMed
99.
Krebs CE, Karkheiran S, Powell JC, Cao M, Makarov V, Darvish H, et al. The sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive parkinsonism with generalized seizures. Hum Mutat. 2013;34:1200–7.CrossRefPubMedPubMedCentral
100.
Sidransky E, Nalls MA, Ph D, Aasly JO, Annesi G, Barbosa ER, et al. Multi-center analysis of glucocerebrosidase mutations in Parkinson disease. N Engl J Med. 2010;361:1651–61.CrossRef
101.
Deng H-X, Shi Y, Yang Y, Ahmeti KB, Miller N, Huang C, et al. Identification of TMEM230 mutations in familial Parkinson’s disease. Nat Genet. Nature Publishing Group; 2016;advance on:733–9.
Metadata
Title
LRRK2 at the interface of autophagosomes, endosomes and lysosomes
Authors
Dorien A. Roosen
Mark R. Cookson
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Molecular Neurodegeneration / Issue 1/2016
Electronic ISSN: 1750-1326
DOI
https://doi.org/10.1186/s13024-016-0140-1

Other articles of this Issue 1/2016

Molecular Neurodegeneration 1/2016 Go to the issue

Methodology

Synaptophysin depletion and intraneuronal Aβ in organotypic hippocampal slice cultures from huAPP transgenic mice

Research article

LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate

Research article

Manifestation of Huntington’s disease pathology in human induced pluripotent stem cell-derived neurons

Review

Induced pluripotent stem cells in Alzheimer’s disease: applications for disease modeling and cell-replacement therapy

Research article

Spinal cord injury induces astroglial conversion towards neuronal lineage

Research article

No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF